Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Next-Generation CAR-Ts Tackle First-Generation Safety, Solid Tumor Challenges

3d illustration of T cells or cancer cells

Related Content

Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy

Jan 23 2018

Too Sick For CAR-T? Kite Reports Cerebral Edema Death

May 09 2017

Engineered T-Cell Company Raises $56m And Lands New CEO

Mar 04 2016

Celyad VP On IP Issues, Development Timelines For CAR-T Therapies

Apr 26 2017

Autolus Raises $80m To Take T-Cell Engineering To The Next Level

Sep 26 2017

Start-Up Obsidian Gets $49.5m To Determine How And When To Activate CAR-T Cells

Dec 07 2017

Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year

Apr 15 2018

Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends

Mar 09 2018

New kid on the CAR-T block: Syncona/UCL form Autolus

Jan 22 2015

Bluebird Flies On 100% Response Rate For Anti-BCMA CAR-T

Jun 06 2017

Related Companies

Poseida Therapeutics, Inc.

Celyad Oncology SA

Novartis AG

Gilead Sciences, Inc.

Kite Pharma, Inc.

Bristol Myers Squibb Company

Genetix Biotherapeutics

Bristol Myers Squibb Company

Autolus Therapeutics plc

University College London

Cancer Research UK

Fate Therapeutics, Inc.

Memorial Sloan Kettering Cancer Center

University of Washington

Fred Hutchinson Cancer Research Center

The Scripps Research Institute (TSRI)

Obsidian Therapeutics, Inc.

Cellectis SA

Eureka Therapeutics, Inc.

Brigham Young University

CRISPR Therapeutics AG

Endocyte, Inc.

Purdue University

Additional Topics

Clinical Trials ImmunoOncology Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window